10:10 AM - 10:25 AM

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

Location: Le Meridian AL Khobar, Saudi Arabia

Social Share

× How can I help you?